We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-8.77%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$152M
AUM Growth
-$18.7M
Cap. Flow
+$1.22M
Cap. Flow %
0.8%
Top 10 Hldgs %
86.83%
Holding
51
New
9
Increased
9
Reduced
8
Closed
2

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$1.47M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$838K
3
ALBO
Albireo Pharma Inc
ALBO
+$808K
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$609K
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$587K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$3.35M
2
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$1.8M
3
AXGN icon
Axogen
AXGN
+$521K
4
CORT icon
Corcept Therapeutics
CORT
+$361K
5
QDEL icon
QuidelOrtho
QDEL
+$233K

Sector Composition

Rank Sector Weight
1 Healthcare 96.14%
2 Energy 2.62%
3 Industrials 0.37%
4 Consumer Staples 0.35%
5 Consumer Discretionary 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$63.3M 41.66%
709,181
-34,870
-5% -$3.35M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$49.9M 32.86%
218,380
– –
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$4.35M 2.86%
52,400
– –
VRML
4
DELISTED
Vermillion, Inc.
VRML
$3.21M 2.12%
2,362,933
-100,000
-4% -$153K
OXFD
5
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.21M 1.45%
177,303
+50,000
+39% +$609K
EQT icon
6
EQT Corp
EQT
$31B
$2.01M 1.32%
77,705
– –
CFRX
7
DELISTED
ContraFect Corporation
CFRX
$1.84M 1.22%
1,419
– –
ARRY
8
DELISTED
Array Biopharma Inc
ARRY
$1.83M 1.2%
112,000
+92,000
+460% +$1.47M
QDEL icon
9
QuidelOrtho
QDEL
$1.19B
$1.76M 1.16%
33,975
-5,000
-13% -$233K
VNDA icon
10
Vanda Pharmaceuticals
VNDA
$327M
$1.48M 0.98%
88,000
– –
OVV icon
11
Ovintiv
OVV
$16.2B
$1.46M 0.96%
26,460
– –
CORT icon
12
Corcept Therapeutics
CORT
$9.72B
$1.24M 0.82%
75,500
-19,500
-21% -$361K
SLNO
13
DELISTED
Soleno Therapeutics
SLNO
$1.23M 0.81%
45,229
– –
XLRN
14
DELISTED
Acceleron Pharma
XLRN
$978K 0.64%
25,000
– –
ATRA icon
15
Atara Biotherapeutics
ATRA
$75.6M
$897K 0.59%
+920
New +$838K
GTHX
16
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$815K 0.54%
+22,000
New +$587K
ALBO
17
DELISTED
Albireo Pharma Inc
ALBO
$782K 0.52%
+24,000
New +$808K
MASI
18
DELISTED
Masimo
MASI
$704K 0.46%
8,000
– –
VCYT icon
19
Veracyte
VCYT
$4.72B
$660K 0.43%
118,767
– –
AXGN icon
20
Axogen
AXGN
$2.12B
$657K 0.43%
18,000
-17,000
-49% -$521K
VYGR icon
21
Voyager Therapeutics
VYGR
$192M
$620K 0.41%
33,000
-10,000
-23% -$216K
SIEN
22
DELISTED
Sientra, Inc.
SIEN
$611K 0.4%
6,330
– –
WMGI
23
DELISTED
Wright Medical Group Inc
WMGI
$595K 0.39%
30,000
– –
CMTA
24
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$576K 0.38%
38,000
+16,000
+73% +$260K
SITO
25
DELISTED
SITO MOBILE, LTD
SITO
$563K 0.37%
140,000
+20,000
+17% +$108K
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Birchview Capital held 51 positions worth $152M, down 11% from $171M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Birchview Capital's Q1 2018 filing shows 9 new, 9 increased, 8 reduced and 2 closed positions. Its largest new stake was Atara Biotherapeutics: 920 shares worth $897K. The largest sale was Celgene Corp, an estimated $3.35M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Energy and Industrials.

  • Birchview Capital's largest Q1 2018 buy was Atara Biotherapeutics: 920 shares worth $897K.
  • Birchview Capital added most to Array Biopharma Inc in Q1 2018, an estimated $1.47M increase.
  • Birchview Capital's biggest Q1 2018 reduction was Celgene Corp, cutting an estimated $3.35M.
  • Birchview Capital fully exited Advanced Accelerator Applications S.A. in Q1 2018, selling an estimated $1.8M.
  • Birchview Capital's ten largest holdings make up 87% of its $152M portfolio in Q1 2018.
  • Birchview Capital opened 9 new positions and closed 2 in Q1 2018.
  • Birchview Capital's portfolio value fell 11% quarter-over-quarter to $152M.

Based on Birchview Capital's 13F filing for Q1 2018, filed 7 May 2018.